Expected Patents Expiry of Biological Products and Kinase inhibitors patent expiry in Europe 2018 – 2027 and CAR-T entrants in 2018. Kinase inhibitor products patent expiry in Europe. Presented here list, is a nonexhaustive one. Brand names are also included.
Prominent biological products patent expiry dates in Europe:
2018: Humira (adalimumab, TNFα inhibitor), indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and juvenile idiopathic arthritis.
The patent expired in October 2018. Price discounts provided by Humira in the first six months reached up to 89%.
2019: Forteo (teriparatide, recombinant protein form of parathyroid hormone), indicated for the treatment of some types of osteoporosis.
2020: Kadcyla (ado-trastuzumab emtansine), indicated for the treatment of HER2-positive metastatic breast cancer (broadly defined here).
2021: Cimzia (certolizumab pegol), indicated for the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
2022: Avastin (bevacizumab), indicated for the treatment of numerous types of cancers and eye diseases.
2023: Perjeta (pertuzumab), indicated for the treatment of HER2-positive breast cancer.
2024: Stelara (ustekinumab), indicated for the regulation of immune-mediated inflammatory disorders.
2025: Simponi (golimumab, TNFα inhibitor), indicated for the treatment of rheumatoid arthritis (combination), active psoriatic arthritis (PsA) and others.
2026: Opdivo (nivolumab), indicated for cancer treatments.
2027: Tecentriq (atezolizumab), indicated for the treatment of urothelial carcinoma treatment after the failure of cisplatin-based chemotherapy (broadly defined here).
This schedule of patent expiries was firstly presented at the Health care innovation forum in Sofia. Bulgarian language version of the document is also available.
For updated information, please bookmark this web page.
Information updates every quarter. The current version is consistent with Q1 2019 updates.